DNA Intercalators and Using Them as Anticancer Drugs

dna intercalators and using them as anticancer drugs

many anticancer drugs in clinical use interact with dna through intercalation, which is process that starts with the transfer of the intercalating molecule from an aqueous environment to the hydrophobic space between two adjacent dna base pairs. in general, intercalatig agents are two types: monofunctional and bifunctional. monofunctional intercalators contain one intercalating unit and bifunct...

Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances.

Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioav...

Transition Metal Intercalators as Anticancer Agents—Recent Advances

The diverse anticancer utility of cisplatin has stimulated significant interest in the development of additional platinum-based therapies, resulting in several analogues receiving clinical approval worldwide. However, due to structural and mechanistic similarities, the effectiveness of platinum-based therapies is countered by severe side-effects, narrow spectrum of activity and the development ...

Antibacterial and Anticancer Drugs - Interaction with DNA

Polyamine analogues as anticancer drugs.

Just over 30 years ago, the late Diane Russell published the first in a series of papers linking polyamines and cancer. These early studies led to a flurry of research activity in the polyamine field that continues to this day attempting to identify a role for the polyamines in cancer development, treatment and/or prevention. The recognition that polyamines are critical for the growth of cancer...